Critical concludes on CP024 intranasal growth hormone trial
CP024 growth hormone nasal spray was safe and well tolerated in the study that administered six dose levels of CP024 in healthy subjects. Pharmacokinetics demonstrated by the nasal
The US Food and Drug Administration (FDA) has declined to approve Unicycive Therapeutics’ resubmitted new drug application (NDA) for oxylanthanum carbonate (OLC) to treat hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.
The collaboration will focus on preclinical and clinical development of therapeutic peptide, developed by Pergamum, with both anti-infective and anti-inflammatory properties. Development activities will be carried out at